HK1114567A1 - Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract - Google Patents

Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract

Info

Publication number
HK1114567A1
HK1114567A1 HK08110145.5A HK08110145A HK1114567A1 HK 1114567 A1 HK1114567 A1 HK 1114567A1 HK 08110145 A HK08110145 A HK 08110145A HK 1114567 A1 HK1114567 A1 HK 1114567A1
Authority
HK
Hong Kong
Prior art keywords
respiratory tract
tissue factor
inflammatory conditions
pathway inhibitor
conditions affecting
Prior art date
Application number
HK08110145.5A
Other languages
English (en)
Inventor
Lars Otto Uttenthal
Original Assignee
Drugrecure Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugrecure Aps filed Critical Drugrecure Aps
Publication of HK1114567A1 publication Critical patent/HK1114567A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
HK08110145.5A 2005-06-24 2008-09-11 Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract HK1114567A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69396805P 2005-06-24 2005-06-24
PCT/IB2006/002602 WO2006136962A2 (en) 2005-06-24 2006-06-23 Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract

Publications (1)

Publication Number Publication Date
HK1114567A1 true HK1114567A1 (en) 2008-11-07

Family

ID=37570814

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08110145.5A HK1114567A1 (en) 2005-06-24 2008-09-11 Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract

Country Status (15)

Country Link
US (3) US20100297099A1 (de)
EP (3) EP1896059B1 (de)
JP (3) JP2008543925A (de)
KR (2) KR20080071116A (de)
CN (2) CN101262880A (de)
AU (2) AU2006273696B2 (de)
BR (2) BRPI0613137A2 (de)
CA (2) CA2612597C (de)
DK (3) DK1906994T3 (de)
HK (1) HK1114567A1 (de)
IL (2) IL188220A0 (de)
NO (2) NO20080433L (de)
RU (2) RU2496516C2 (de)
WO (3) WO2006136963A2 (de)
ZA (2) ZA200800251B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008071197A1 (en) * 2006-12-11 2008-06-19 Drugrecure Aps Methods for treating cystic fibrosis or pneumonia with bacterial infection via pulmonary administration of fosfomycin
KR102068010B1 (ko) 2012-07-04 2020-01-20 제트제트 바이오테크 엘엘씨 염증성 피부 질환의 치료
PT3137102T (pt) * 2014-04-16 2021-09-28 Zz Biotech Llc Apc para utilização no tratamento de cicatrização cutânea anormal
CA3036553A1 (en) * 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
US5378614A (en) * 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
SE9200541D0 (sv) * 1992-02-24 1992-02-24 Kabi Pharmacia Ab New usee of omega-3-fatty acids
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
JP2001523949A (ja) * 1996-11-08 2001-11-27 オクラホマ メディカル リサーチ ファウンデーション 改変したプロテインｃおよびその使用方法
WO1998032459A1 (en) * 1997-01-29 1998-07-30 University Technology Corporation Plasminogen activator as an anti-inflammatory agent
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6049577A (en) * 1998-05-28 2000-04-11 Glenayre Electronics, Inc. Header synchronization detector
AR023819A1 (es) * 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
JP4848092B2 (ja) * 2000-02-01 2011-12-28 石原産業株式会社 ジアミノトリフルオロメチルピリジン誘導体を含有する肺不全の治療剤又は予防剤
ATE286122T1 (de) * 2000-02-02 2005-01-15 Lilly Co Eli Protein c derivate
DE60138364D1 (de) * 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
US6933367B2 (en) * 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
IL158615A0 (en) * 2001-05-02 2004-05-12 Novo Nordisk As Modified factor vii in treatment of acute lung injury or acute respiratory distress syndrome
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
CN1604790A (zh) * 2001-10-15 2005-04-06 希龙公司 通过施用组织因子途径抑制剂(tfpi)治疗严重性肺炎
US7189289B2 (en) * 2002-02-08 2007-03-13 Sk Corporation Cleaning agent and method for cleaning heater tubes
CN1838964A (zh) * 2002-04-25 2006-09-27 斯克里普斯研究学院 肺病的治疗与预防
EA008038B1 (ru) * 2003-01-08 2007-02-27 Чирон Корпорейшн Стабилизированные водные композиции, содержащие ингибитор пути метаболизма, тканевого фактора (tfpi) или вариант ингибитора пути метаболизма тканевого фактора
US20060205749A1 (en) * 2003-03-13 2006-09-14 Yuzuru Abe Remedy and/or preventive for lung diseases
WO2005042011A1 (en) * 2003-11-04 2005-05-12 Novo Nordisk A/S Pharmaceutical composition comprising a protein c polypeptide and a blood glucose regulator
WO2006026998A1 (en) * 2004-09-10 2006-03-16 Pharmaorigin Aps Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis
WO2006042017A2 (en) 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway

Also Published As

Publication number Publication date
ZA200800255B (en) 2009-04-29
WO2007012976A2 (en) 2007-02-01
IL188220A0 (en) 2008-03-20
IL188221A0 (en) 2008-03-20
JP2008543925A (ja) 2008-12-04
ZA200800251B (en) 2009-04-29
US20100160218A1 (en) 2010-06-24
NO20080433L (no) 2008-03-19
DK1906994T3 (da) 2014-07-21
RU2496515C2 (ru) 2013-10-27
AU2006273696B2 (en) 2012-08-30
RU2496516C2 (ru) 2013-10-27
JP2013151510A (ja) 2013-08-08
WO2006136963A3 (en) 2007-07-12
EP1896059A2 (de) 2008-03-12
EP1898945B1 (de) 2012-12-19
NO20080434L (no) 2008-03-17
EP1906994A2 (de) 2008-04-09
CA2612646C (en) 2015-11-24
EP1896059B1 (de) 2012-12-19
RU2008102656A (ru) 2009-07-27
KR20080074085A (ko) 2008-08-12
EP1906994B1 (de) 2014-04-23
WO2007012976A3 (en) 2007-07-12
US20100297099A1 (en) 2010-11-25
AU2006273696A1 (en) 2007-02-01
JP2008543926A (ja) 2008-12-04
US8088728B2 (en) 2012-01-03
WO2006136962A3 (en) 2007-07-12
AU2006260599A1 (en) 2006-12-28
EP1898945A2 (de) 2008-03-19
WO2006136962A2 (en) 2006-12-28
BRPI0613137A2 (pt) 2010-12-21
KR20080071116A (ko) 2008-08-01
DK1896059T3 (da) 2013-04-08
RU2008102655A (ru) 2009-07-27
CN101262879B (zh) 2013-04-10
CA2612597A1 (en) 2007-02-01
BRPI0611710A2 (pt) 2011-12-20
CA2612597C (en) 2015-03-31
WO2006136963A2 (en) 2006-12-28
CN101262880A (zh) 2008-09-10
US20100279925A1 (en) 2010-11-04
CN101262879A (zh) 2008-09-10
CA2612646A1 (en) 2006-12-28
DK1898945T3 (da) 2013-03-25

Similar Documents

Publication Publication Date Title
HK1137807A1 (en) Diagnosis of infections or inflammatory diseases of the airways and lungs associated with heart failure
IL193230A (en) Use of benzoxoborol derivatives in the preparation of drugs for the treatment of inflammatory diseases
EP1827555A4 (de) Endoluminale verabreichung von anästhesie
IL204723A0 (en) Combination comprising purine derivatives and other compounds and the use thereof for the treatment of inflammatory and obstructive airway diseases
GB0611131D0 (en) Nicotine inhalation therapies - smoking cessation and other medical uses
EP2051760A4 (de) Verabreichung einer atemtherapie
EP2046430A4 (de) Verabreichung einer atemtherapie
PL2170848T3 (pl) Pochodne pirazynonu i ich zastosowanie w leczeniu chorób płuc
DK3542869T3 (da) Engangssøvn- og åndedrætsmonitor
EP2049054A4 (de) Nasale und orale patientenschnittstelle
EP2032156A4 (de) Zusammensetzungen und verfahren zur abgabe von sauerstoff
IL222542A (en) Use of a compound to prepare a drug to inhibit and diagnose proteinuria in the lung
EP1744740A4 (de) Phenoxyalkylcarbonsäurederivat bei der behandlung von entzündlichen erkrankungen
AP2627A (en) New form of administration of racecadotril
GB2443336B (en) Spiruchostatin analogues and their medicinal use
IL194185A0 (en) Formuations of low dose diclofenac and beta-cyclodextrin
EP2086646A4 (de) Nasenkatheter mit internen und externen luftströmungen
EP1755635A4 (de) Behandlung von entzündlicher atemwegserkrankung
ZA200809725B (en) Preparation of antibody-or antibody-fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
EP1843781A4 (de) Zusammensetzung zur prävention, behandlung und diagnose von chronischen entzündlichen atemwegserkrankungen
HK1114567A1 (en) Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract
BRPI0718388A8 (pt) etiqueta adesiva com agente amargante e agentes fluidificantes para secreções naturais das vias aéreas
EP2018178A4 (de) Verabreichung von agonist-antagonisten an opioidabhängige patienten
EP1782808A4 (de) Mittel zur prävention oder behandlung von chronischer entzündlicher lungenkrankheit
EP2123172A4 (de) Verfahren zur vorbeugung von krankheiten bei ferkeln im absetzstadium

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170623